Physician profile
Daniel Blecker
NPI 1154393684
$6,389.47
in general payments reported to CMS, 2019-2025
34 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $285 · 2021: $612 · 2022: $667 · 2023: $1,220 · 2024: $1,365 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,827.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,959.12 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $752.19 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $567.47 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.87 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $302.04 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $280.55 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $269.22 | 2019-2025 | |
| Gilead Sciences, INC. | $231.93 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $182.19 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $172.00 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $162.34 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $135.40 | 2020-2024 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $97.33 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $90.77 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $81.08 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $71.39 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $69.94 | 2020-2021 | |
| Qol Medical, LLC | $60.15 | 2021-2023 | Sucraid |
| Biofire Diagnostics, LLC | $58.97 | 2019 | |
| Merck Sharp & Dohme LLC | $52.97 | 2020-2024 | Dificid, Zinplava, Zerbaxa |
| Daiichi Sankyo INC. | $45.36 | 2024-2025 | Injectafer |
| Genzyme Corporation | $39.93 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $33.77 | 2023 | |
| Endo Pharmaceuticals INC. | $33.46 | 2019 | |
| Shionogi INC | $32.90 | 2019 | |
| Ironwood Pharmaceuticals, INC | $28.73 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $26.29 | 2024 | |
| Olympus America INC. | $19.44 | 2024 | Endoclot Phs |
| Recordati_rare_diseases_inc. | $19.22 | 2025 | Panhematin |
| Evoke Pharma, INC. | $17.54 | 2023 | Gimoti |
| Organon LLC | $17.03 | 2025 | Hadlima, Renflexis |
| Medtronic, INC. | $15.44 | 2021 | |
| Ucb, INC. | $14.20 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Blecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.